{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Seifert R"],"funding":["Deutsche Krebshilfe"],"pagination":["2845-2852"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9712103"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["36(12)"],"pubmed_abstract":["The randomized PETAL trial failed to demonstrate a benefit of interim FDG-PET (iPET)-based treatment intensification over continued standard therapy with CHOP (plus rituximab (R) in CD20-positive lymphomas). We hypothesized that PET analysis of all lymphoma manifestations may identify patients who benefitted from treatment intensification. A previously developed neural network was employed for iPET analysis to identify the highest pathological FDG uptake (max-SUV<sub>AI</sub>) and the mean FDG uptake of all lymphoma manifestations (mean-SUV<sub>AI</sub>). High mean-SUV<sub>AI</sub> uptake was determined separately for iPET-positive and iPET-negative patients. The endpoint was time-to-progression (TTP). There was a significant interaction of additional rituximab and mean-SUV<sub>AI</sub> in the iPET-negative group (HR = 0.6, p < 0.05). Patients with high mean-SUV<sub>AI</sub> had significantly prolonged TTP when treated with 6xR-CHOP + 2 R (not reached versus 52 months, p < 0.05), whereas max-SUV<sub>manual</sub> failed to show an impact of additional rituximab. In the iPET-positive group, patients with high mean-SUV<sub>AI</sub> had a significantly longer TTP with (R-)CHOP than with the Burkitt protocol (14 versus 4 months, p < 0.01). Comprehensive iPET evaluation may provide new prognosticators in aggressive lymphoma. Additional application of rituximab was associated with prolonged TTP in iPET-negative patients with high mean-SUV<sub>AI</sub>. Comprehensive iPET interpretation could identify high-risk patients who benefit from study-specific interventions."],"journal":["Leukemia"],"pubmed_title":["Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial."],"pmcid":["PMC9712103"],"funding_grant_id":["107592","110515"],"pubmed_authors":["Fendler WP","Seifert R","Rahbar K","Herrmann K","Schafers M","Ferdinandus J","Sandach P","Umutlu L","Kersting D","Hanoun C","Weckesser M","Reinhardt HC","Rischpler C","Huttmann A","von Tresckow B","Duhrsen U"],"additional_accession":[]},"is_claimable":false,"name":"Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial.","description":"The randomized PETAL trial failed to demonstrate a benefit of interim FDG-PET (iPET)-based treatment intensification over continued standard therapy with CHOP (plus rituximab (R) in CD20-positive lymphomas). We hypothesized that PET analysis of all lymphoma manifestations may identify patients who benefitted from treatment intensification. A previously developed neural network was employed for iPET analysis to identify the highest pathological FDG uptake (max-SUV<sub>AI</sub>) and the mean FDG uptake of all lymphoma manifestations (mean-SUV<sub>AI</sub>). High mean-SUV<sub>AI</sub> uptake was determined separately for iPET-positive and iPET-negative patients. The endpoint was time-to-progression (TTP). There was a significant interaction of additional rituximab and mean-SUV<sub>AI</sub> in the iPET-negative group (HR = 0.6, p < 0.05). Patients with high mean-SUV<sub>AI</sub> had significantly prolonged TTP when treated with 6xR-CHOP + 2 R (not reached versus 52 months, p < 0.05), whereas max-SUV<sub>manual</sub> failed to show an impact of additional rituximab. In the iPET-positive group, patients with high mean-SUV<sub>AI</sub> had a significantly longer TTP with (R-)CHOP than with the Burkitt protocol (14 versus 4 months, p < 0.01). Comprehensive iPET evaluation may provide new prognosticators in aggressive lymphoma. Additional application of rituximab was associated with prolonged TTP in iPET-negative patients with high mean-SUV<sub>AI</sub>. Comprehensive iPET interpretation could identify high-risk patients who benefit from study-specific interventions.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-04-04T13:46:25.34Z","creation":"2025-04-04T13:46:25.34Z"},"accession":"S-EPMC9712103","cross_references":{"pubmed":["36241697"],"doi":["10.1038/s41375-022-01713-y"]}}